HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise against hard-to-treat breast cancer
Disease control CompletedThis study tested a new drug (TQB3616) combined with fulvestrant in 122 people with a type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see if the combination could shrink tumors or slow the cancer's growth. Participants had either received one prior tr…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising drug combo shows progress against advanced breast cancer
Disease control CompletedThis study tested whether adding the drug ribociclib to standard hormone therapy helps slow the growth of advanced breast cancer in Chinese women. About 327 women with a specific type of breast cancer (HR+, HER2-) took part. The main goal was to see how long the cancer stayed und…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC